Untargeted Metabolomics for Primary Aldosteronism

Primary Aldosteronism Clinical Trial

— PUMPAP  

Official title:

Pilot Untargeted Metabolomics for Primary Aldosteronism in Plasma (PUMPAP)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06076473
• Other study ID #: LHS001
• Status: Recruiting
• Start date: January 19, 2023
• Est. completion date: January 19, 2025

Study information

• Verified date: December 2023
• Source: Liverpool University Hospitals NHS Foundation Trust
• Contact: Sarah Davies, MChem MSc
• Phone: 0151 706 4245
• Email: sarah.davies[@]liverpoolft.nhs.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Primary aldosteronism (PA) is a common and likely under-diagnosed cause of secondary hypertension with associated cardiovascular morbidity and mortality. Current diagnosis comprises screening, confirmatory testing and sub-type classification (lateralisation) to distinguish unilateral disease (requiring surgery) from bilateral disease (requiring medical management). This multi-step process is complex and variable with a lack of uniformity in diagnostic protocols, standardised/reference assay methodologies, and diagnostic thresholds. There is evidence in the literature that targeted serum steroid panels may have a role in diagnosis of PA, and both targeted steroid panels and untargeted metabolomics in serum and urine are a promising area of research.

This study aims to identify and recruit participants (n=40; 20 with confirmed PA and 20 with other causes of hypertension) willing to donate lithium heparin plasma for a metabolomics pilot study. This plasma will be interrogated through untargeted metabolomics using gas/liquid chromatography-mass-spectrometric methods and computational data processing to allow power calculations and inform experimental design for future studies. The utility of metabolites from the metabolomics dataset will be evaluated by comparison against current biomarkers for screening, diagnosis and lateralisation as well as radiology and histology acquired through routine diagnostic work-up. The long-term aim for larger studies is to identify suitable candidate analytes in plasma for future development into targeted, clinically-useful analyte panels.

Description:

Participant Recruitment

• Suitable participants will be identified by members of their care teams, for whom screening, confirmatory testing and lateralisation will be / have been completed at LUHFT.

• Potential participants will be approached by a member of the study team seeking consent. Saline infusion testing and adrenal vein sampling are key points in the diagnostic work-up for participant recruitment for non-PA and PA cohorts, respectively.

• Consenting participants will have lithium heparin plasma collected and stored until the requisite sample size has been reached (n=40; 20 with PA and 20 with PA excluded by aldosterone:renin ratio at screening or saline infusion confirmatory testing). A lithium heparin tube will be used for routine renal profiles requested as part of saline infusion tests or adrenal vein sampling to avoid requirements for any additional blood tubes. The sample will be centrifuged and separated into two aliquots. One aliquot for metabolomic analysis at the University of Liverpool and one for storage within LUHFT until the end of the study (2 years) in case data validation is required. Clinical, biochemical, radiological and histological information from routine care will help to classify participants into PA (n=20) and non-PA (n=20) groups, as well as to assign lateralisation status. Ideally there will be equal representation from unilateral left, unilateral right and bilateral disease in the PA sub-set.

• Recruitment will close after 18 months.

Laboratory Analysis

• Untargeted metabolomics analysis using chromatography-mass spectrometric methods will be performed on lithium heparin plasma from all consenting participants. An aliquot of this sample will be transferred to the University of Liverpool for analysis and used to destruction (with no backwards transfer).

Data Analysis

• Computation analysis of the data set will be used to screen for novel PA biomarkers that could be further investigated in later studies.

• Univariate and multivariate methods will be applied. These will include univariate statistical and AUROC calculations, adjusted logistic regression techniques, unsupervised (clustering/visualisation) and supervised (classifier-based) multivariate methods

• Power calculations and pilot data set analysis will inform future experimental design.

Sample Storage

• Primary aliquots will be stored at LUHFT for up to 18 months awaiting analysis. They will then be transferred in one batch to the University of Liverpool and used to destruction.

• Secondary aliquots of biological material (which are intended as a back-up in case data validation is required) will be stored under appropriate conditions to preserve integrity until the end of the study. Samples will be disposed of after completion of the pilot study (2 years) in line with routine laboratory practice.

Data storage

• Storage of analytical and metadata will be for a period of five years. It will be stored on a secure computer on the Royal Liverpool University Hospital (RLUH) network.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: January 19, 2025
• Est. primary completion date: January 19, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Criteria:

Screening for PA to be performed in people with:

• sustained blood pressure (BP) above 150/100 mm Hg on each of three measurements obtained on different days, with hypertension (BP >140/90 mm Hg) resistant to three conventional antihypertensive drugs (including a diuretic), or controlled BP (<140/90 mm Hg) on four or more antihypertensive drugs.

• hypertension and spontaneous or diuretic-induced hypokalaemia.

• hypertension and adrenal incidentaloma.

• hypertension and sleep apnoea.

• hypertension and a family history of early onset hypertension or cerebrovascular accident at a young age (<40 years).

• all hypertensive first-degree relatives of people with PA.

Subset of people being screened for PA who are eligible for inclusion in this study:

• 18 years of age or older.

• People under the care of LUHFT.

• Able to give informed consent.

• Having lithium heparin plasma samples collected as part of their routine care.

Exclusion Criteria:

• Under 18 years of age.

• Unable to give informed consent.

• Insufficient clinical/biochemical/radiological/histological information to accurately assign patients to PA or non-PA subsets.

Related Conditions & MeSH terms

• Hyperaldosteronism
• Primary Aldosteronism

Intervention

Diagnostic Test:
• Untargeted metabolomics
Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.

Locations

Country	Name	City	State
United Kingdom	Liverpool University Hospitals NHS Foundation Trust	Liverpool	Merseyside

Sponsors (1)

Lead Sponsor	Collaborator
Liverpool University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Untargeted metabolomics	Identification of candidate biomarkers	2 years